Molecular discoveries alter our view of inflammatory bowel disease: A review from scientific, clinical, and laboratory perspectives

American Journal of Clinical Pathology

Volumn 119, Issue 4, 2003, Pages 524-539

  Staros, Eric B ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Genome; IBD; Laboratory; NOD2

Indexed keywords

BORTEZOMIB; CYTOKINE; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; LDP 2; MOLECULAR MARKER; NATALIZUMAB; PROTEASOME; PROTEASOME INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CARD15 PROTEIN, HUMAN; CARRIER PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; SIGNAL PEPTIDE;

APOPTOSIS; CLINICAL RESEARCH; CROHN DISEASE; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; DRUG RESPONSE; ENTERITIS; GENETIC MARKER; HUMAN; MISSENSE MUTATION; MOLECULAR BIOLOGY; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN 2 GENE; PRIORITY JOURNAL; REGULATOR GENE; REVIEW; ULCERATIVE COLITIS; GENETICS; GENOME; METHODOLOGY; PATHOLOGY;

CARRIER PROTEINS; GENOME, HUMAN; HUMANS; INFLAMMATORY BOWEL DISEASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR BIOLOGY; NOD2 SIGNALING ADAPTOR PROTEIN;

EID: 85047689401     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/7W3ETL9NQ9RHHX61     Document Type: Review

References (87)

1. Cho JH. Update on the genetics of inflammatory bowel disease. Curr Gastroenterol Rep. 2001;3:458-463.
2. Polito JM, Childs B, Mellits ED, et al. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996;111:580-586.
3. Galon J, Aksentijevich I, McDermott MF, et al. TNFRSFIA mutations and autoinflammatory syndromes. Curr Opin Immunol. 2000;12:479-486.
4. Hanauer SB, Rutgeerts PJ, Sandborn WJ. Conquering the clinical challenges of IBD: optimizing anti-TNF-alpha-alpha therapy. Medscape. Available at: http://www.medscape.com/ CMECircle/Gastroenterology/2001/CME03/pnt-CME03.html. Accessed January 2002.
5. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133.
6. Yacyshyn B, Bowen-Yacyshyn MB, Shanahan W. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease. Curr Opin Mol Ther. 1999;1:332-335.
7. Blau EB. Familial granulomatous arthritis, iritis, and rash. J Pediarr. 1985;107:689-693.
8. Tromp G, Kuivaniemi H, Rapheal S. Genetic linkage of familial granulomatous inflammatory arthritis, skin rash and uveitis to chromosome 16. Am J Hum Genet. 1996;59:1097-1107.
9. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29:19-20.
10. Hugot J, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
11. Inohara N, Ogura Y, Chen FF. Human Nodl confers responsiveness to bacterial lipopolysaccharides. J Biol Chem. 2001;276:2551-2554.
12. Kaster DL, O'Shea JJ. A fever comes in from the cold. Nat Genet. 2001;29:241-242.
13. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
14. McDermott EM, Smillie DM, Powell RJ. The clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index and extended family. Mayo Clin Proc. 1997;72:806-817.
15. Mulley J, Saar K, Hewitt G, et al. Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Genet. 1998;62:884-889.
16. McDermott MF, Ogunkaolade BW, McDermott EM, et al. Linkage of familial Hibernian fever to chromosome 12p13. Am J Hum Genet. 1998;62:1446-1451.
17. McDermott MF, Askentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFRI, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97:133-144.
18. Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol. 2001;159:387-397.
19. Beg AA, Finco TS, Nantermet PV. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IkappaB-alpha: a mechanism for NF-kappa B activation. Mol Cell Biol. 1993;13:3301-3310.
20. Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol. 2001;116:637-646.
21. Herrmann JL, Briones F, Brisbay S, et al. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional bcl-2 and p53. Oncogene. 1998;17:2889-2899.
22. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-2622.
23. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res. 2001;100:11-17.
24. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. Cell Biochem. 2001;82:110-122.
25. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of NF-kappa B, cell survival, tumor growth and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7:1419-1428.
26. Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A. 1998;95:15671-15676.
27. Sakurai H, Kohsaka H, Liu MF, et al. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest. 1995;96:2357-2363.
28. Wilder RL, Allen JB, Wahl LM, et al. The pathogenesis of group A streptococcal cell wall-induced polyarthritis in the rat: comparative studies in arthritis resistant and susceptible inbred strains. Arthritis Rheum. 1983;26:1442-1451.
29. Conner EM, Brand S, Davis JM, et al. Proteasome inhibition attenuates nitric oxide synthetase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther. 1997;282:1615-1622.
30. Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998;101:1163-1174.
31. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145-1157.
32. Maini R, St Clair EW, Breedveld F, et al, for the ATTRACT Study Group. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet. 1999;354:1932-1939.
33. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95:3469-3477.
34. Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis. 2001;7(suppl 1):S17-S22.
35. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
36. Asakura H, Yao T, Matsui T, et al. Efficacy of treatment with chimeric monoclonal antibody (infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J Gastroenterol Hepatol. 2001;16:763-769.
37. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
38. Feagan BG, Enns R, Fedorak RN, et al. Infliximab for the treatment of Crohn's disease: efficacy, safety, and pharmacoeconomics. Can J Clin Pharmacol. 2001;8:188-198.
39. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000;95:3189-3194.
40. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis. 2001;7(suppl 1):S30-S33.
41. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83-85.
42. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
43. Gordon FH, Lai CWY, Hamilton MC. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha-4-integrin in active Crohn's disease. Gastroenterology. 2001;121:268-274.
44. Burns RC, Rivera-Nieves J, Moskaluk CA, et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology. 2001;121:1428-1436.
45. Marshal JK. LDP-02 (Millennium). Curr Opin Investig Drugs. 2001;2:502-504.
46. Fedorak RN, Gangl A, Elson CO, et al, for the Interleukin Inflammatory Bowel Disease Cooperative Study Group. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology. 2000;119:1473-1482.
47. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
48. Cush JJ, Matteson EL. Hotline: FDA advisory committee reviews safety of TNF inhibitors. Available at 2002:http://www.rheumatology.org/research/hotline/0901tng. html. Accessed March 15, 2002.
49. Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol. 1996;156:1646-1653.
50. Charles PJ, Smeenk RJ, DeJong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo controlled trials. Arthritis Rheum. 2000;43:2383-2390.
51. Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther. 2001;15:1101-1108.
52. Cohen RB, Dittrich KA. Anti-TNF-alpha therapy and malignancy: a critical review. Can J Gastroenterol. 2001;15:376-384.
53. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Special report: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328-346.
54. Miettinen M. New challenges in the identification of gastrointestinal stromal tumors and other possible KIT-driven tumors [editorial]. Am J Clin Pathol. 2002;117:183-185.
55. Wang SC, Zhang L, Hortobagyi GN, et al. Targeting HER2: recent developments and future directions for breast cancer patients. Semin Oncol. 2001;28(6 suppl 18):21-29.
56. Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359-367.
57. Moran A, Jones A, Asquith P. Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn's colitis. Scand J Gastroenterol. 1995;30:356-360.
58. Linskens RK, Van Bodegraven AA, Schoorl M, et al. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci. 2001;46:644-648.
59. Ling PR, Schwartz JH, Jeevanandam M, et al. Metabolic changes in rats during a continuous infusion of recombinant interleukin-1. Am J Physiol. 1996;270:E305-E312.
60. Propst A, Propst T, Herold M, et al. Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 1995;7:1031-1036.
61. Casini-Raggi V, Kam L, Chong YJ, et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease: a novel mechanism of chronic intestinal inflammation. J Immunol. 1995;154:2434-2440.
62. Freeman BD, Buchman TG. Interleukin-1 receptor antagonist as therapy for inflammatory disorders. Expert Opin Biol Ther. 2001;1:301-308.
63. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-2204.
64. Kaul KL, Molecular detection of Mycobacterium tuberculosis: impact on patient care. Clin Chem. 2001;47:1553-1558.
65. Ohshima S, Saeki Y, Mima T, et al. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol. 1999;19:305-313.
66. Nikolaus S, Raedler A, Kuhbacker T, et al. Mechanisms in failure of infliximab in Crohn's disease. Lancet. 2000;356:1475-1479.
67. Van Heel DA, Satsangi AH, Carey DP, et al. Inflammatory bowel disease: progress toward a gene. Can J Gastroenterol. 2000;14:207-218.
68. Hampe J, Schreiber S, Shaw SH, et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet. 1999;64:808-816.
69. Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn's disease. Nat Genet. 2001;29:223-228.
70. Daly MJ, Rioux JD, Schaffner S, et al. High resolution haplotype structure in the human genome. Nat Genet. 2001;29:229-232.
71. Nemetz A, Kope A, Molnar T, et al. Significant differences in the interleukin-1beta and interleukin receptor antagonist gene polymorphism in a Hungarian population with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:175-179.
72. Bioque G, Bouma G, Crusius JB, et al. Evidence of genetic heterogeneity in IBD, I: the interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur J Gastroenterol Hepatol. 1996;8:105-110.
73. Schulte CM, Dignass AU, Goebell H, et al. Genetic factors determine the extent of bone loss in inflammatory bowel disease. Gastroenterology. 2000;119:909-920.
74. Witkin SS, Gerber S, Ledger WJ. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis. 2002;34:204-209.
75. Tountas NA, Casini-Raggi V, Yang H, et al. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology. 1999;117:806-813.
76. Carter MJ, Di Giovine FS, Cox A, et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology. 2001;121:805-811.
77. Dieckgraefe BK, Stenson WF, Korzenik JR, et al. Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol Genomics. 2000;4:1-11.
78. Warner EE, Dieckgraefe BK. Application of genome-wide expression profiling by high-density DNA arrays to the treatment and study of inflammatory bowel disease. Inflamm Bowel Dis. 2002;8:140-157.
79. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet. 2001;10:445-456.
80. Zervos A, Gyuris J, Brent R. Mxil, a protein that specifically interacts with max to bind myc-max recognition sites. Cell. 1993;72:223-232.
81. Inohara N, Ogura Y, Nunez G. Nods: a family of cytosolic proteins that regulate the host response to pathogens. Curr Opin Microbiol. 2002;5:76-80.
82. White SH, Wimley WC, Selsted MD. Structure, function, and membrane integration of defensins. Curr Opin Struct Biol. 1995;5:521-527.
83. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3,7 and 12. Nat Genet. 1996;14:199-202.
84. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002;122:854-866.
85. Hess JL. The advent of targeted therapeutics and implications for pathologists [editorial]. Am J Clin Pathol. 2002;117:355-357.
86. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025-1030.
87. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608.